About 40% of AML patients exhibit increased activity of the NF-kB signaling pathway, and it is constitutively active in CD34+/CD38- blasts from M1, M2, M4, and M5 AML patients [94,95]. The gene discussed is NFKB1; the disease is acute myeloid leukemia.